 |
 |
 |
|
|
|
December 23 - 29, 2004
Defining the Adequacy of Peritoneal Dialysis 
(Ramesh Khanna, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
What are the potential pitfalls in interpreting PETT curves? What are potential reasons for falsely high creatining values? Falsely low or high glucose values? How can we correct errors by looking at both creatinine and glucose curves together? What are some practical PD prescriptions for problem patients in whom the PETT has changed? How can we adjust for sodium and potassium excretion by residual renal function by modifying the PD prescription?
Renal Week
2004 Audio
now in MP3PGE Course: ADVANCES IN RESEARCH. NEW PARADIGMS IN VASCULAR BIOLOGY: RENAL IMPLICATIONS
Angiogenesis
- Pericyte Recruitment in Angiogenesis;
(Betsholtz) (more...)
Development
- The Zebrafish as a Model Organism to Study Vascular Development;
- VEGF and the Development of the Renal Vasculature;
- Lymphangiogenesis/ Lymphatics in Renal Disease;
(Weinstein, Quaggin, Kerjaschki) (more...)
Atherosclerosis, Inflammation, and Repair
- Current Mechanisms of Lipid Dependent Vascular Wall Injury;
- Overview of Immune Mechanisms in Atherogenesis: Role of Adaptive Immunity;
- Role of Innate Immunity and Atherosclerosis;
- Chemokines and Their Receptors in Atherogenesis;
- Haplo-Insufficiency of Elastin Causes Vascular Dysfunction and Hypertension;
- Calcification of the Vessel Wall;
- Biology of Stent Stenosis and Potential Therapies;
(Han, Hansson, Witstum, Charo, Mecham, Giachelli, Clowes) (more...)
December 15 - 22, 2004
Glomerular Disease. Part Two (Biopsy cases)
(Gerald Appel, MD and Helmut Rennke, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
You have a patient with proteinuria 4-5 g/day in a solitary kidney. Do you biopsy him? What are the likely diagnoses? What are the long-term consequences of uninephrectomy? Unilateral renal agenesis? Next case is a 72 year old man with 18 g/day of proteinuria. What serologic tests should be done? Should biopsy be done? What are the likely diagnoses? What did the biopsies show? (Technical note: Source audiotape of bad quality; beyond our control. Sorry. Please print out "small slide version".)
Audiofiles
Now in MP3STATE OF THE INDUSTRY
- A Wall Street Perspective;
(Burgansky) (more...)
December 7 - 14, 2004
Glomerular Disease. Part One (Biopsy cases)
(Gerald Appel, MD and Helmut Rennke, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
A patient with smouldering IGAN presents with acute worsening of renal function. What are the diagnostic steps that should be taken? What is the differential diagnosis? What are the options for treatment? A man with previously normal renal function presents with acute worsening of creatinine and benign urine sediment. What are the pitfalls in making a diagnosis? How can the urinalysis help? What are possible causes? What did the biopsy show and how was the patient treated?
Audiofiles
Now in MP3Consensus Topics (continued)
- DEBATE: Icodextrin - A New Era in Peritoneal Dialysis?;
- Diabetes in Chronic Kidney Disease: Tragedy & Challenge;
- Glycemic Control of Diabetes in the Dialysis Unit: How to do it; Evidence for its value;
- Diabetes & Sudden Death: Why are Diabetics Asymptomatic & Strategies for Prevention;
- ADQI: CRRT: Recommendations for Practice and Research; Research in ARF Animal Models to Definitions; Blood Purification in Non-Renal Disease;
- New Information from DOPPS: : Estimating the Potential of Life Years Saved by Changing Practice Patterns;
(Lameire, Bargman, Bakris, McMurray, McCullough, Kellum, Port) (more...)
ANNA CE
(Article Free, $CE)Celebrating 50 Years of Transplantation: Past, Present, and Future
(Patricia Weiskittel, RN, MSN, CNN, CS, ARNP, BC. ANNA 35th Annual Meeting, Washington DC, April, 2004)
November 20 - December 6, 2004
The Kidney in Pregnancy
(Phyllis August, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
How does one manage and counsel pregnant women with various forms of renal disease? How does pregnancy affect renal disease? How does renal disease affect pregnancy? How should one evaluate and treat new onset hypertension, azotemia, or proteinuria during pregnancy?
Audiofiles
Now in MP3Keynote Address
- Gene polymorphism in acute renal failure : the promise of immuno-modulation;
(Jaber) (more...)
Consensus Topics
- Anemia/Iron Symposium : Role of New Erythropoeitins;
- Anemia/Iron Symposium : Iron, Anemia & Congestive Heart Failure;
- Anemia/Iron Symposium : Balancing Iron;
- Anemia/Iron Symposium : PRCA;
- When Good Water Goes Bad: How it Happens, Clinical Consequences & Possible Solutions;
(Besarab, Silverberg, Sargent, Nissenson, Lonnemann) (more...)
ANNA CE
(Article Free, $CE)Chronic Kidney Disease and Dyslipidemia
(Sally Campoy RN, MS, CS, CNN, ANP. ANNA 35th Annual Meeting, Washington DC, April, 2004)
November 9 - 19, 2004
Calcium and Phosphorus: Key Physiologic Principles
(David Bushinsky, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
What are factors affecting ionized, complexed, and protein-bound serum calcium? How do the calcium-sensing receptor, PTH, and vitamin D interact to maintain calcium homeostasis? What are the basics of intestinal calcium absorption? Bone calcium accretion and absorption? What are factors controlling calcium handling by the kidney? What are the basic factors that control phosphorus balance? What hormones and other factors influence phosphorus excretion by the kidney?
Secondary Hypertension Including Chronic Kidney Disease 
(Robert Toto, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
When should we think of secondary hypertension? How do we approach renovascular disease? Atheroembolism? Primary aldosteronism? Pheo? Various genetic conditions that cause hypertension, including GRA, Liddle Syndrome, Gordon Syndrome, Geller Syndrome? Hypertension due to chronic kidney disease?
Audiofiles
Now in MP3Technology & Therapeutics Session
- Bioartificial Kidney: Progress on the Renal Assist Device in Acute & Chronic Renal Failure;
- Application of Sorbents in ARF & ESRD: Middle Molecule & Cytokine Removal;
- Bone Morphogenic Proteins: Potential Agent for Reversing CRF Progression;
- Non-Specialist Ultrasound Measurement of Access Flow: New Technology;
- HIV Hemopurifier: Potential Efficacy of Therapy Combined with Fusion Inhibitors;
- Dialysis without Membranes: How and Why?;
- State of the industry: a wall street perspective;
(Humes, Winchester, Kullari, Vilkomerson, Tullis, Leonard, Burgansky) (more...)
ANNA CE
(Article Free, $CE)Alport's Syndrome Strep D (AKA enterococcus)
(Mary Schira, PhD, RN, APRN, BC, ACNP.
ANNA 35th Annual Meeting, Washington DC, April, 2004)
October 28 - November 3, 2004
Chronic Inflammation and Renal Disease: Practical Aspects. Part Two of Two.
(George Kaysen, MD, PhD; ASN Board Review Course; San Francisco, CA, August, 2004)
How is survival in ESRD patients affected by LDL cholesterol, serum albumin and CRP level? Is IL-6 a better marker? What are roles of serum amyloid A and fibrinogen? Which markers should we measure? Does membrane biocompatibility affect inflammatory cytokines? Water quality? Covert infections such as thrombosed access or periodontal disease? To what extent can the inflammatory syndrome be treated?
Audiofiles
Now in MP3Keynote Address
- Cardiac Diseases in Kidney Disease Patients; Current Understanding and Opportunities for Change;
(A. Levin) (more...)
Consensus Topics
- Atherosclerosis in ESRD : Genesis of Atherosclerosis: Can it be identified and its progress slowed early in CKD?;
- Atherosclerosis in ESRD : What is the practical approach to atherosclerosis in ESRD?;
- Atherosclerosis in ESRD : Vascular Calcification: Mechanisms & Control;
- Calcimimetics vs. Vitamin D: What are their relative roles?;
- Volume Status in ESRD : Comparison between PD and HD; influence of peritoneal solutions;
- Volume Status in ESRD : Blood pressure and volume control: treatment strategies; importance of water versus sodium removal;
- Volume Status in ESRD : Dry weight; new developments;
- Volume Status in ESRD : Importance of residual renal function; impact on volume status; pathophysiology of decline;
(Tsao, Ritz, Chen, Drueke, Lameire, Leunissen, Greenwood, Pecoits-Filho) (more...)
October 21 - 27, 2004
Chronic Inflammation and Renal Disease: Practical Aspects. Part One of Two.
(George Kaysen, MD, PhD; ASN Board Review Course; San Francisco, CA, August, 2004)
How do you distinguish between malnutrition and inflammation? What are the clinical limitations of measures of nutrition? Does malnutrition per se lower serum albumin? What are variables that predict serum albumin in HD and PD patients? What can we learn about measures of muscle mass, fat free mass, and malnutrition / inflammation? What effect does inflammation have on EPO sensitivity? (Part Two next week).
Audiofiles
Now in MP3How to Manage a Dialysis Center: Medical Director's Role Session
- Federal Regulatory Guidelines: Why Subpart U is Important;
- Medical Director Responsibilities & Compensation: What You Need to do and Why;
- Ensuring Quality in the Dialysis Unit; Use of Teams & CQI to Achieve Goals;
- Prevention of Medical Errors: Clinical Areas to Watch;
(Riley Jr, Lazarus, Provenzano, Kliger) (more...)
International Care Models for CKD: Methods & Economics
- United States;
- Europe (3 separate systems);
- Singapore;
(Crooks, Will, Ramirez) (more...)
October 13 - 20, 2004
Herbs and Heavy Metals: A Recipe for Kidney Failure. Part Two. Heavy Metals.
(Warren Kupin, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
What is the pathophysiologic basis of heavy metal toxicity to the kidney? What are sources of lead exposure? Manifestations of acute and chronic lead toxicity? How do we diagnose chronic lead toxicity? What is the role of EDTA chelation? When should one suspect cadmium toxicity? How does it manifest in the kidney? How can gold harm the kidneys? How is gold nephrotoxicity treated? How does mercury harm the kidney? Arsenic? What implication do these heavy metals have for progression of CKD?
Audiofiles
Now in MP3How to Manage a Dialysis Center: Administrative, Technical Session
- How Do Dialyzers and Dialysis Machines Really Work?;
- Understanding Water Treatment and the Importance of Dialysate Composition;
- How to Setup and Run a Successful PD Program;
- Understanding Modality Kinetics: HD vs. PD;
- Understanding the Finances of a Dialysis Facility;
(Ronco, Hoenich, Golper, Gotch, DeOreo) (more...)
ANNA CE
(Article Free, $CE)How Peritoneal Dialysis Works
Karen T. Kelley
Comparison of Peritoneal Dialysis Solutions
Terri L. Crawford-Bonadio and Jose A. Diaz-Buxo
Troubleshooting Non-Infectious Peritoneal Dialysis Issues
Donna E. Maaz
October 6 - 12, 2004
Herbs and Heavy Metals: A Recipe for Kidney Failure. Part One. Herbs.
(Warren Kupin, MD; ASN Board Review Course; San Francisco, CA, August, 2004)
What is the scope of herbal medicine use in the U.S. What types of patients use herbal medicines? What are potential problems with herbal diuretics? What nephrotoxic adulterants and contaminants can be found? How do Chinese herb nephropathy, analgesic nephropathy, and Balkan nephropathy differ? What is the pathogenesis of star fruit nephrotoxicity? What are problems with Ma Huang (ephedra)? When can herbal therapy worsen or cause hyperkalemia? What are potential problems with licorice, St. John's wort, and grapefruit juice? Are creatine supplements of risk to the kidneys? (Next week: Part Two - Heavy Metals).
Bones, Moans, and Groans: Skeletal Disorders in Chronic Kidney Disease 
(Kim Alleman, MS, RN, FNP, CNN. ANNA 35th Annual Meeting, Washington DC, April, 2004)
How do we differentiate etiologies and pathophysiologies of various skeletal disorders in CKD? How can one explain pharmacologic strategies utilized to minimize bone disease in renal failure? What factors must one consider in managing bone disease after transplantation? (Editor's note: This talk is in the free zone, but ANNA-sponsored CE requires payment of a fee to ANNA).
ADC
audiofiles
Now in MP3Special Session on Aging
- Keynote Address: The Biology of Aging.;
- Can Aging be Prevented?;
- Cardiovascular and Kidney Aging;
- The Institute for Healthcare Improvement Project;
- Teaching the Elderly Patient;
(Masoro, Richardson, Hinojosa-Laborde, Thompson, Moseley) (more...)
September 28 - October 5, 2004
ABO Incompatible and Positive Crossmatch Renal Transplantation: A New Paradigm
(Lloyd Ratner, MD; ASN Renal Week; San Diego, November, 2003)
Potential live donors frequently are excluded due to positive crossmatch or to ABO incompatibility. What are new approaches to enable transplantation in the sensitized recipient? What are results using IVIg and/or plasmapheresis? What is the optimal adjunctive immunosuppressive therapy? What are clinical results with this new approach? What are strategies for ABO-incompatible transplantation? What are the clinical results with plasmapheresis and Cytogam? What would be the impact on donor kidney shortage of adoption of these newer protocols?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Vascular Access: In Search of Solutions
- Identifying the Problem: A Review of DOPPS Data;
- Vascular Access: The New ESRD Network Scope of Work;
- In the Trenches: A Successful Fistula Improvement Project;
- The Institute for Healthcare Improvement Project;
- A European Perspective on Vascular Access Management: The EDTNA Collaborative Research Project;
(Mapes, Payne, Nguyen, Brouwer, Elseviers) (more...)
Rumors About the Demise of Home Hemodialysis are Greatly Exaggerated
- FRCP How to Accelerate Revitalization of Home HD;
- Home HD Is Superior to In-Center HD. A Patient's Perspective;
- Home HD Is the Best Therapy for Me;
(Moran, Weintraub, Peckham) (more...)
September 14 - 27, 2004
Vein Mapping for Placement of Fistulas
(Vo Nguyen, MD; ASN Renal Week; San Diego, November, 2003)
How do you set up a vascular access program such that you have almost 100% patients using AV fistulas? Dr. Nguyen has done this, and he describes his methods of achieving this goal in detail. This talk focuses on the numerous types of AV fistulas that can be created at various stages in a patient's dialysis access history, and gives special tips for placing AV fistulas in patients with compromised veins or arteries. The selection criteria for artery and venous size are emphasized, as are two functional tests: Arterial pulse contour and flow increase after release of the clenched fist, and venous dilatation after compression.
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Biocompatible Dialysis
- Bioincompatible Toxins and Spallation in Dialysate Equipment: What Are They? Are They Important? How to Measure Them? Part I;
- Bioincompatible Toxins and Spallation in Dialysate Equipment: What Are They? Are They Important? How to Measure Them? Part II;
- Clinical Effects of Ultrapure Dialysate;
(Kjellstrand, Canaud) (more...)
How to Measure the Dose of Dialysis
- Time and Frequency of HD: The Hemodialysis Product (HDP);
- Middle Molecule Clearance (Dialysis Index);
- Time Average Concentration (TAC), Time Average Deviation (TAD);
- Small Molecule Clearances: Kt/V - Which Formula?;
- Global Clinical Assessment or Medical Doctor Time per Patient (MDt/P);
(Oreopoulos, Vanholder, Schneditz, Barth, Twardowski) (more...)
August 31 - September 13, 2004
Vascular Compliance: Impact on Cardiovascular and Renal Disease Risk
(Stanley Franklin, MD; ASN Renal Week; San Diego, November, 2003)
How do blood vessels stiffen with age, and how does this affect systolic, diastolic, and pulse pressures? What implications does this have for the power of these 3 pressures to predict cardiovascular events? What ten clinical insights can we gain from this? (1) Prediction of CV risk; (2) Wide pulse pressures with reduced cardiac ejection; (3) Pulse pressure as a predictor of therapeutic response; (4) Pulse pressure and resistance to goal therapy; (5) Vascular calcification, stiffness, and pulse pressure; (6) Diastolic BP as a CV predictor in young adults; (7) Additional diagnostic value of diastolic BP at any age; (8) Recognizing when cuff pulse pressure values are misleading; (9) Choosing the proper treatment for wide PP HTN; (10) PP vs. SBP, DBP, and MAP in predicting CV risk.
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Maximizing AV Fistula Utilization in Dialysis Patients
- Increasing AV Fistulas: A Surgeon's Perspective;
- How Can Interventional Nephrologists Increase the Use of AV Fistulas?;
- HD Catheters and Subcutaneous Access Devices: Their Role As Bridge Devices;
(Lumsden, Beathard, Saad) (more...)
HD Schedules and Prescription: What, How and Why
- Introduction;
- Conventional HD;
- Long HD;
- Hemeral Dialysis ;
- Nocturnal HD;
(Ronco, Greenwood, Charra, Ting, Pierratos) (more...)
August 20 - 26, 2004
Long-Term Peritoneal Membrane Preservation
(Nicholas Topley, PhD; ASN Renal Week; San Diego, November, 2003)
What are the causative factors of membrane dysfunction in PD? What are the roles of acute and chronic inflammation? Fibrogenic processes? Dialysis solutions? How can we preserve long-term peritoneal membrane function? How can we optimize our choice of dialysis solutions? Do additives play a role? How can we reduce inflammation?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
To Reuse or Not to Reuse
- Introduction;
- Mortality, Morbidity and Cost;
- Advantages and Disadvantages of Heat Reprocessing of Dialyzers and Lines;
(Twardowski, Lowrie, Kenley) (more...)
New Technical Advances in HD Monitoring: Tools or Toys?
- The Meaning of On-Line Monitoring;
- On-Line Monitoring of Blood Volume and Cardiovascular Function;
- On-Line Monitoring of Temperature and Thermal Energy;
- On-line Monitoring of Clearance (Ronco, Guest, Schneditz, Gotch) (more...)
August 13 - 19, 2004
Phosphorus-PTH-Bone: Achieving Balance and Avoiding Extraosseous Calcification
(ASN Renal Week; Official Evening Symposium; San Diego, November, 2003)
Dr. Silver: Vitamin D inhibits PTH mRNA transcription in the nucleus; how does hypocalcemia block this effect? How do calcium and phosphorus affect PTH mRNA degradation? How do phosphorus and calcimimetic drugs affect PTH cell proliferation? Dr. Shanahan: What evidence do we have that vascular calcification is an active process? Why are matrix Gla protein, fetuin, and other intermediary factors of potential interest in modulating vascular calcification? Dr. Malluche: How effective a phosphate binder is lanthanum carbonate in vitro and in animal models? What are lathanum pharmacokinetics? What do the early patient studies of lanthanum vs. calcium-containing phosphate binders suggest?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Blood Pressure Issues in Hemodialysis
- How to Diagnose Hypertension in HD Patients;
- What Is the Impact of Hypertension on Cardiovascular End Points?;
(Reams, Alpert) (more...)
Intriguing HD and PD Differences
- The Relationship of Body Mass to Survival in HD and PD;
- Are Middle Molecule Clearances Better in HD or PD?;
- Are Hospital Days Greater in HD or PD Patients?;
- Mental Function in HD and PD;
- Do the ADEMEX and HEMO Studies Confirm the Peak Concentration Hypothesis?;
(Tzamaloukas, Vanholder, Mehrotra, Bargman, Kathuria) (more...)
August 5 - 11, 2004
The Importance of Residual Renal Function and its Maintenance in Patients on Dialysis
(Thomas Golper, MD; ASN Renal Week; San Diego, November, 2003)
What is the evidence comparing decline in residual renal function (RRF) during hemodialysis vs. during PD? What factors promote preservation of RRF in HD vs. in PD patients? What is the importance of RRF and how is it linked to survival? How does an understanding of RRF change our interpretation of survival studies in dialysis? What can we do to help maintain RRF?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Important Updates
- Dialysis Outcomes and Practice Patterns Study (DOPPS);
- United States Renal Data System (USRDS) Report;
- The HEMO Study;
(Young, Collins, Rocco) (more...)
Gender and Hemodialysis
- Role of Gender in Consideration of HD Prescription;
- Does Gender Affect Outcomes of HD Access?;
- Psychosocial Issues in Women on HD;
- Hormone Use in Dialysis-Dependent Women: The HELP Study;
- Pregnancy in Dialysis Patients;
(Depner, Beathard, Zimmerman, Reams, Krane) (more...)
July 28 - August 3, 2004
Renal Challenges during Bone Marrow and Peripheral Blood Stem Cell Transplantation
(Laura Dember, MD; ASN Renal Week; San Diego, November, 2003)
The indications for myoablative stem cell transplantation are growing: What are they? Apart from renal toxicity of immunosuppressive and anti-neoplastic drugs, what are common causes for acute renal failure after this procedure? A number of case histories of autologous SCT are presented; each one illustrating a specific problem and how it was addressed. What are renal complications of allogenic stem cell transplantation? What are potential preventive drugs on the horizon?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Calcimimetics: A Novel Approach to Controlling Secondary Hyperparathyroidism in Dialysis Patients
- Challenges in Managing Secondary HPT and Achieving the New K/DOQI Laboratory Targets;
- Developing and Implementing Treatment Protocols for the Use of Cinacalcet;
(Martin, McCann) (more...)
Diagnostic and Interventional Nephrology Session
- PD Access by the Nephrologist;
- Renal Ultrasonography;
- Vein Mapping in Planning for Fistulas and Tunneled Dialysis Catheter Procedures;
- Arteriovenous Fistula Cannulation;
- Vascular Access Monitoring;
- Endovascular Procedures for AV Access Maintenance;
(Ash, O'Neill, Beathard, Brouwer, Saad) (more...)
July 20 - 26, 2004
Combined Pulmonary and Renal Impairment: Difficulties in Distinguishing Volume Contraction from Volume Overload
(Steven Hollenberg, MD; ASN Renal Week; San Diego, November, 2003)
How good are our clinical skills in diagnosing fluid overload? What are the technological methods that help identify fluid overload in the ICU setting? What information can we obtain from trans-thoracic as well as trans-esophageal echo? How useful is monitoring CVP or pulmonary capillary wedge pressure? What are the pitfalls in these measurements? How useful are esophageal Doppler and pulse contour analysis?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Protecting the Peritoneal Membrane in Patients: Evidence-Based Recommendations
- Introduction and Overview;
- Will a Dialysis Solution pH >7.0 Protect the Membrane? What is the Evidence?;
- Is Bicarbonate Better for the Membrane than Lactate? What is the Evidence?;
- Does Avoidance of High Glucose Concentrations Protect the Membrane? What is the Evidence?;
- Prevention of Chemical Peritonitis from Solution Contaminants - The Facts;
- Are There Additives to Dialysis Solutions That Will Protect the Membrane? What is the Evidence?;
- Are There Ways to Limit Fibrosis Related to Peritonitis? What is the Evidence?;
- Advantages of Products with Reduced Glucose Degradation Products and/or Advanced Glycosylation End Products. What is the Evidence?;
(Oreopoulos, Martis, Mactier, Blaker, Faber, Topley, Haraldson, Holmes) (more...)
July 12 - 18, 2004
Antagonizing Vasopressin: AVP Receptor Antagonists
(Joseph Verbalis, MD; ASN Renal Week; San Diego, November, 2003)
What are the options for antagonizing the effects of vasopressin (V)? What are the main V subtypes and which drugs block which receptor? What V receptor blockers are in clinical trials and how do they differ? What are the potential indications for their use? Are their advantages to use a drug that blocks more than one receptor subtype? What are the pharmacokinetics of these new agents? What are preliminary clinical trial results in SIADH? In heart failure? In treating hyponatremia?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
PD Fundamentals (Day 2)
- Non-Infectious Complications of PD;
- Dialysis and Transplantation: Choice of Dialysis Pre-Transplant;
- Timing of Access Removal;
- Transplant Success - With or Without Dialysis? / Dialysis Post Transplant;
- Dialysis Solution Composition: Glucose and Alternatives;
- Lactate and Alternatives;
- PD Catheters and Connectology;
- Management of Diabetics on PD;
- Chronic Inflammation and PD;
- Management of Anemia;
(Bargman, Venkataraman, Brennan, Blake, Kathuria, Nichols, Dasgupta, Stenvikel, Nissenson) (more...)
July 5 - 11, 2004
Long-Term Benefits of Pancreas Transplantation
(Bryan Becker, MD; ASN Renal Week; San Diego, November, 2003)
What are the benefits of transplanting a pancreas either simultaneously with, or after, transplanting a kidney? What are the graft and patient survival data? What is the effect on quality of life? On recurrence of mesangial cell expansion in the allograft? What are effects on retinopathy and vision? On peripheral vascular disease? Amputation risk? Blood pressure control? Cardiac risk and cardiac function? Neuropathy? Sexual function? Effects on pregnancy outcome?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
PD Fundamentals (Day 1)
- Applied Peritoneal Physiology: Solute Removal;
- Ultrafiltration ;
- Electrolyte Removal;
- Current Adequacy Guidelines;
- CAPD and APD prescriptions;
- Outcomes in Diabetics, Elderly and Malnourished Patients - USRDS Data;
- Peritonitis Case Studies;
- Update on Continuous Flow Peritoneal Dialysis;
(Haraldson, Khanna, Nolph, Burkart, Schrieber, Collins, Faber, Amerling) (more...)
June 28 - July 4, 2004
NephroAsia. Selected Talks (Lecture Notes) (Part 2 of 2)
(NephroAsia Congress, Singapore, February, 2004)
Note: These are not full slide/audio talks. We present the lecture notes (black and white copies of the slides as a .pdf file) only. The audiofiles did not become available for technical reasons.
Locatelli: What are the rationale, strategy, and guidelines for treating anemia in ESRD? What is NESP (darbepoetin) and how does it differ from recombinant human erythropoietin? How does pharmacokinetics of NESP differ from r-HuEPO? What is CERA (Continuous Erythropoiesis Receptor Activator)? What are its pharmacokinetics? Clinical study results? What are EPO mimetic compounds? Erythropoeitin fusion proteins? Macdougall: What is the differential diagnosis of EPO resistance? When should anti-erythropoietin antibodies be suspected? What are the causative drugs? How does SC vs. IV administration figure in? What should diagnosis and management be? Tattersall: What are the main impurities and compounds of concern in water for dialysis? What is the strategy for protecting against them? How is inflammation linked to less than optimally purified dialysis water? What is the evidence that high quality water improves outcome?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Clinical Topics I (Focus on PD)
- The Status of Tidal PD;
- Debunking of Myths about PD;
- The Role of PD in Managing Hepatic Failure with Ascites;
- First Year Results with Icodextrin in the USA;
- How to Increase the PD Population in Your Program;
- An Integrated (HD and PD) Home Dialysis Program;
- Myths about PD (Flanigan, Piraino, Mactier, Teitelbaum, Finkelstein, Oreopoulos) (more...)
June 20 - 26, 2004
NephroAsia. Selected Talks (Lecture Notes) (Part 1 of 2)
(NephroAsia Congress, Singapore, February, 2004)
Note: These are not full slide/audio talks. We present the lecture notes (black and white copies of the slides as a .pdf file) only. The audiofiles did not become available for technical reasons.
Karupaiah: How are eating patterns in Asia changing? What is the role of food taboos and traditional medicine? Ethnic preferences? How common is malnutrition? What education programs have been shown to work in this population? Hi Bahl Lee: (Basic science talk) How do high glucose levels work through reactive oxygen species to promote oxidative injury to mesangial cells? How is protein kinase C involved? What signalling pathways are affected? How can this be prevented? Shanyan Lin: What are the major causes of acute renal failure in China, and how are these changing over time? What is the success rate of using high-volume CVVH in China? What are the effects of ascorbic acid dialysate on oxidative stress? Of liposome-containing dialysate on removal of protein-bound toxins? Of TNF monoclonal antibody immunoadsorption on ARF caused by endotoxin? Lee Kang Hoe: What are the results with the MARS™ system (recirculating, albumin-containing dialysate) in liver failure in Singapore? What are the indications? The potential pitfalls? The complications?
Part 2 (four additional presentations) will follow in 1-2 weeks.
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Safety of Intravenous Iron: From the Laboratory to the Clinic
- Pharmacokinetics and Red Cell Utilization of Iron Hydroxide Sucrose Complex in Anemic Patients;
- Safety of IV Iron in Clinical Practice: Implications for Anemia Management Protocols;
- Labile Iron in IV Iron Agents;
(Aronoff, Reed, Van Wyck) (more...)
Quotidian HD and HF Update: Optimal Frequency and Time: Theoretical and Practical Considerations
- Influence of HD Time and Frequency on Removal of Low Molecular Weight Solutes - Importance of Compartmentalization;
- Is Short HD (2 - 2.5 hr, 6 Times Weekly) Sufficient for Optimal Dialysis?;
- Are We Overdialyzing Patients with Nocturnal HD?;
- Is Quotidian Hemofiltration Better than Quotidian HD?;
(Leypoldt, Kjellstrand, Pierratos, Zimmerman) (more...)
June 13 - 19, 2004
How To Manage The Patient With Severe Hyperparathyroidism: The Role Of Newer Agents To Suppress Parathyroid Hormone Release
(Stuart Sprague, DO; ASN Renal Week; San Diego, November, 2003)
What are the goals of therapy in renal bone disease management? How do the key K/DOQI guidelines fit in? What are the current limitations of calcium-containing P (phosphate) binders? Sevelamer? Lanthanum? Which vitamin D analogues are best? When should they be used? What is the physiology of the calcium-sensing receptor? What to clinical trials with cinacalcet reveal?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Opening General Session and Keynote Addresses
- Choice of Modality for Treatment of the Critically Ill Patient with Acute Renal Failure;
- Is Chronic Inflammation an Important Causative Factor for Cardiovascular Disease in Dialysis Patients?;
(Ronco, Stenvinkel) (more...)
How to Evaluate the Peritoneal Membrane Transport Characteristics
- Accelerated Peritoneal Examination (APEX);
- Mass Transfer Area Coefficient (MTAC);
- PD Capacity (PDC);
- Peritoneal Equilibration Test (PET);
- Standard Permeability Analysis (SPA);
(Verger, Vonesh, Haralsdon, Tarakji, Krediet) (more...)
Controversy: Speed Up or Slow Down
- Fallacies of Low Speed HD;
- Fallacies of High Speed HD;
(Gotch, Barth) (more...)
June 6 - 12, 2004
Medical and Surgical Approaches to Severe Hyperparathyroidism
(Masafumi Fukagawa, MD, PhD; ASN Renal Week; San Diego, November, 2003)
What are indications for parathyroidectomy? When do we reach the "point of no-return" at which point medical therapy usually fails? Can ultrasound help determine when medical therapy will fail based on gland size and/or vascularity? What can we learn from serum fibroblast growth factor (FGF-23) levels in CKD and ESRD in terms of parathyroid disease? What are indications and relative contraindications for direct vitamin D injection into the parathyroid gland?
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Managing Fluid and Sodium Balance and Blood Pressure in HD and PD
- Sodium Balance Should Be Easy, But it Isn't;
- Population Differences in Sodium Intake and the Impact on Dialysis - An Analysis of the INTERSALT Study;
- What! No Ketchup? Sodium in Dialysis Patients - the Reality ;
- An Epidemic of Hypertension in PD Patients: What Is to Blame?;
- What Dialysis Solution Sodium Concentration Should Be Used for CAPD, NIPD and CCPD?;
- What Dialysate Sodium Concentration Should Be Used for Sodium Balance in Short, High Efficiency HD? Does Sodium Modeling Help?;
- Blood Pressure Control in Long Thrice-Weekly HD;
- Blood Pressure Control in Quotidian HD;
(Sherman, Reams, McCann, Negoi, Oreopoulos, Van Stone, Charra, Lindsay) (more...)
May 28 - June 5, 2004
Addressing Current Challenges and Clinical Implications In Iron Management
(ASN Renal Week; Official Evening Symposium; San Diego, November, 2003)
Dr. Suki: What are the newer ways of detecting iron deficiency, including reticulocyte Hb content and soluble tranferrin receptor levels? What can we learn about patients who have high ferritin levels but low levels of transferrin saturation? Dr. Agarwal: To what extent do various iron preparations release free or non-transferrin bound iron? What implications does this have for cardiovascular disease, oxidative stress, and risk of infection? Dr. Feldman: What can we learn about the risks of IV iron administration from large databases? What do the Europeans find in terms of IV iron and bacteremia risk? What did analysis of USRDS data show? What additional information do we have from a longitudinal analysis of the Fresenius patient database, attempting to control for various confounding factors potentially associated with administration of large amounts of IV iron?
ASN Renal Week
audiofiles
Now in MP3Audiofile selection - ASN 2003 (San Diego) (5-10 talks)
Practice Issues in CKD Management
- Cardiovascular Risk Management and Outcomes in CKD;
- CKD Clinics: What Works and What Doesn't;
- Preparing the CKD Patient for ESRD;
(Szczech, Provenzano, Haley) (more...)
Literature Review The Year in Nephrology: Transplantation and Dialysis
- Dialysis;
- Transplantation;
(Burkart, Gonwa) (more...)
Novel Mechanisms for Preeclampsia
- Pathophysiology of Preeclampsia: Insights from Animal Models;
- Role of Inflammatory Cytokines;
- The Role of Sflt-1 and VEGF in Preeclampsia;
- Agonistic AT1 Receptor Antibodies in Preeclampsia;
(Granger, Conrad, Karumanchi, Dechend) (more...)
Prevention of Hemodialysis Vascular Access Stenosis
- Vascular Access Dysfunction: Overview of the Problem and Clinical Trials;
- Lessons From the World of Coronary Stenosis;
- Molecular and Gene Therapy for Neointimal Disease;
(Dixon, Kuntz, Dzau) (more...)
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Clinical Topics
- Preventing and Treating Pruritus in Dialysis Patients;
- Dialysis Issues in Hepatitis and HIV Patients;
- Update on Vascular Calcification in Dialysis Patients;
(Swinfard, Ahuja, Misra) (more...)
Industry Speaks I
- Quality Steps in Dialysis Therapies;
- Cost Benefit of Electronic Medical Records in Care of Dialysis Patients;
- Measurements for Dialysis Patients - From Advanced Assay Methodology to Improved Clinical Outcome;
- The Emerging Role of Subcutaneous Vascular Access Devices for HD Access;
- Improving Outcomes Using Blood Volume Monitoring;
(Warns, Pollak, Cantor, Moran, Guest) (more...)
Complications of long-term dialysis
- Morbidity and mortality;
- Cardiovascular complications;
- Bone disease;
- Dialysis amyloidosis;
(Greenwood, Alpert, Amerling, Charra) (more...)
May 21 - 27, 2004
The Role of Parathyroidectomy: Medical Perspective
(Eric Cohen, MD; ASN Renal Week; San Diego, November, 2003)
What are the indications for, and the benefits of, parathyroidectomy? Is survival improved? What are trends in use of parathyroidectomy? Is use of vitamin D beneficial? How does one approach refractory hyperparathyroidism after renal transplantation? (Next week: a Japanese perspective).
ASN Renal Week
audiofiles
Now in MP3Audiofile selection - ASN 2003 (San Diego) (5-10 talks)
Bioenergetics, Weight Control, and Renal Disease Risk
- Maintenance of Body Weight: Peripheral Adiposity Signals and Their Actions in the Brain;
- Insulin Resistance and Obesity in Diabetes;
- Cytokines, Food Intake, and the Metabolic Syndrome;
(Seeley, Hansen, Wisse) (more...)
Expanding the Donor Pool
- Use of Marginal Cadaveric Donors;
- Non-Directed Donation;
- ABO Incompatible and Positive Cross-Match Renal Transplantation: A New Paradigm;
- New UNOS Policy on Extending the Donor Pool;
(Kaplan, Matas, Ratner, Danovitch) (more...)
The Systemic Effects of Phosphorus
- The Sodium-Phosphate Co-Transporter in Health and Disease;
(Lederer) (more...)
Basic Science for Clinical Nephrologists: New and Emerging Diagnostic/Therapeutic Techniques and Their Clinical Applications
- Polycystic Kidney Disease;
- Water Metabolism;
(Torres, Verbalis) (more...)
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Actions of a New PTH Inhibitor and Implications for Its Use
- What Is the 3rd Generation PTH Assay and How Do 3rd Generation Assays Differ?;
- What to Look for in Assessing the Value of an Existing or New PTH Test;
(Amerling, Cantor) (more...)
PD Case Forum
- Post-transplant ascites;
(Schreiber) (more...)
Complications of long-term dialysis
- Morbidity and mortality;
- Cardiovascular complications;
- Bone disease;
- Dialysis amyloidosis;
(Greenwood, Alpert, Amerling, Charra) (more...)
May 7 - 20, 2004
A Novel Approach to Controlling Secondary Hyperparathyroidism (HPT): Targeting the Calcium-Sensing Receptor
(ASN Renal Week; Official Evening Symposium; San Diego, November, 2003)
Dr. Martin: What are the K/DOQI recommendations regarding control of calcium (Ca), phosphorus (P) and PTH? How often should we measure 25(0H) vitamin D levels and what is the target? What are target Ca, P, and Ca x P levels? What are target PTH values for different stages of CKD and how are these affected by the newer, more specific PTH assays? Dr. Nemeth: How does the calcium sensing receptor affect parathyroid cells? How do calcimimetic drugs work? What is their pharmacokinetics? What aspects of parathyroid hormone and parathyroid gland structure do these drugs affect? Dr. Block: In the Phase III studies of cinacalcet completed so far, what were the results? How were patients characterized at entry? How did baseline PTH level affect achievement of goal PTH values? How do these drugs affect Ca, P, and the Ca x P product?
ASN Renal Week
audiofiles
Now in MP3Audiofile selection - ASN 2003 (San Diego) (5-10 talks)
Cholesterol Biosynthesis and Degradation: Implications for the Kidney
- Cellular Metabolism of Cholesterol;
- Changes in Cellular Cholesterol Following Injury;
- Vascular Inflammation and Injury;
- Inflammation and Mesangial Foam Cells;
(Tabas, Zagner, Nicholson, Moorhead) (more...)
Fetal Antecedents of Adult Disease: The Child Is Father to the Man
- Fetal Origins of Cardiovascular Disease;
- Nephron Number and Adult Hypertension;
- Experimental Prenatal Programming of Hypertension;
- Perinatal Influences on Sympathetic Nervous System Function;
(Barker, Amann, Vehaskari, Young) (more...)
New Insights into Acid-Base Physiology
- The Renal Physiology of Pendrin;
- Localization of Rh Glycoproteins, a New Family of Ammonium Transporters, in the Kidney and Other Organs;
- The Role of the NHE3/Megalin Complex in the Physiology of the Proximal Tubule;
(Wall, Wiener, Biemesderfer) (more...)
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Development of New Peritoneal Dialysis Solutions: What is on the Horizon?
- Peptides As Osmotic Agents;
- Hyaluronan As an Additive;
- PHD Alternative Buffers;
(Martis, Breborowicz, Tzamaloukas) (more...)
Icodextrin: Highlights of the First New U.S. PD Solution in Two Decades
- Part One;
- Part Two;
(Burkart, Divino) (more...)
Updates on Important PD Topics
- Worldwide Experiences Using PD for Early (Healthy) Initiation Followed by Incremental Dosing;
- Clinical Implications of Peritoneal Vascular Area;
- The Status of Post-ADEMEX and K/DOQI Guidelines for PD Initiation and Adequacy;
(Rocco, Pecoits-Filho, Burkart) (more...)
April 28 - May 4, 2004
Effective Business Approaches for Your Nephrology Practice (Part 2 of 2)
(RPA 2004 Annual Meeting, Washington, DC. March, 2004)
Note: These are not full slide/audio talks. We present the audiofiles, and where there were slides, we provide a black and white copy of the slides as lecture notes in a .pdf file. RPA members and HDCN key zone users have full access to these RPA 2004 talks. Please call the RPA for a login ID if you are an RPA member. McMurray: Non-Traditional Revenue Streams for Nephrology Practice Germain, Maddux: Tools Necessary to Meet the Changing Business Needs of Nephrology Practice Amedia: Financial Implications of Risk Sharing in Nephrology: Disease Management Kenney: Valuation of Medical Practices Velez: Exit Strategies for Senior Partners Pascoe: Practice Personnel - Who to Hire and When
ASN Renal Week
audiofiles
Now in MP3Audiofile selection - ASN 2003 (San Diego) (5-10 talks)
Peroxisome Proliferator Activated Receptors and the Kidney
- PPARs in Kidney and Urologic Diseases ;
- The Essential Role of PPAR in Proximal Tubular Repair During Acute Renal Failure ;
- Mesangial Cell PPAR and Renal Extracellular Matrices ;
- PPARs in Diabetic Renal Disease ;
(Guan Y., Portilla D., McCarthy K., Hsueh W.) (more...)
Novel Mechanisms of Progression in Diabetes Mellitus
- Glucose Transporters and Cell Signaling: Implications for Diabetic Complications ;
- Novel Rho-family GTPases in Diabetic Kidney Disease ;
- Transduction of Insulin Signals by the hnRNP K-Protein ;
- Protein Translation: Uncharted Territory in Diabetic Nephropathy ;
(Brosius F., Kanwar Y., Bomsztyk K., Kasinath B.) (more...)
Improving Clinical Outcome in Chronic Dialysis: Critical Evaluation of Available Data
- Small and Large Uremic Toxins ;
- Chronic Dialysis Prescriptions: Which Parameters to Use? ;
(Vanholder R., Leypoldt J.) (more...)
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Metabolic Acidosis in Chronic Kidney Disease Patients
- Pathophysiology of Metabolic Acidosis in Renal Disease ;
- Nutritional Consequences of Metabolic Acidosis ;
- Renal Osteodystrophy and Metabolic Acidosis ;
- Optimal Correction of Metabolic Acidosis in Dialysis Patients - What Should the Minimum Bicarbonate Be? ;
(Mitch E.W., Mehrotra R., Finkelstein F., Mactier R.) (more...)
Choice of PD Modality
- When Is APD Preferred Over CAPD? ;
- When Is CAPD Preferred Over APD? ;
(Schreiber M., Atalla J.) (more...)
DEBATE: Inflammation is a Major Cause of Protein-Energy Malnutrition, Morbidity and Mortality in Maintenance Dialysis Patients
- Yes ;
- No ;
(Kopple J., Mitch W.) (more...)
April 21 - 27, 2004
Effective Business Approaches for Your Nephrology Practice (Part 1 of 2)
(RPA 2004 Annual Meeting, Washington, DC. March, 2004)
Note: These are not full slide/audio talks. We present the audiofiles, and where there were slides, we provide a black and white copy of the slides as lecture notes in a .pdf file. Mr. Brady Augustine did not want to post his talk, but is willing to send copies of his slides to interested parties. Please contact the RPA if you want a copy of his slides. RPA members have full access to the web posting of the RPA 2004 talks. Please call the RPA for a login ID if you are a member. Weiss: RPA Year in Review. Blaser: RPA Advocacy Agenda. Sadler: 30 Years of RPA: A Retrospective. Schulman: Louis Diamond Lecture: Integrating Business Principles into Nephrology Practice.
ASN Renal Week
audiofiles
Now in MP3Audiofile selection - ASN 2003 (San Diego) (5-10 talks)
Nephrology Quiz & Questionnaire
- Fluid and Electrolytes ;
- Transplantation ;
- ESRD ;
- Glomerular / Tubular Disorders ;
(Goldfarb, Hricik, Prichard, Appel) (more...)
Recent Discoveries in Pathogenesis and Treatment of Renal Cancer
- Tumor Suppression by the von Hippel-Lindau Protein ;
- The TRC8 Hereditary Renal Cancer ;
- Hypoxia-Inducible Factor-1 in Development of Renal Cancer ;
(Iliopoulos, Gemmill, Wiesener) (more...)
Cardiovascular Risk Factors in Chronic Kidney Disease
- Chronic Kidney Failure as a Risk Factor for Cardiovascular Disease ;
- Dyslipidemia ;
- Sudden Death ;
(Sarnak, Kronenberg, Herzog) (more...)
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Preserving Residual Renal Function (RRF) in PD and HD Patients
- How Can We Avoid Non©Steroidal Anti© Inflammatory Drugs and Still Manage Pain? ;
- How Can We Minimize the Decline of RRF with Contrast Studies? What is the Evidence? ;
- Does RRF Decline More Rapidly in HD Than in PD? How Good Is the Evidence? ;
- What Levels of Blood Pressure Control and What Agents Best Preserve RRF? How Good is the Evidence? ;
- Antibiotics in Dialysis Patients Avoiding Bad Choices and Wrong Doses ;
- Is the Rate of Decline of RRF Linked to the Chronic Inflammatory Syndrome? What is the Evidence? ;
- Maximal Acceptable Blood Sugars in Diabetic Patients. Achieving Glucose Control? What is the Evidence? ;
(Teitelbaum, Bargman, Misra, Mehrotra, Finkelstein, Stenvinkel, Flanigan) (more...)
April 13 - 19, 2004
Uric Acid, the Kidney, and the Pathogenesis of Hypertension. Part Two of Two.
(Richard Johnson, MD; ASN Renal Week; San Diego, November, 2003)
In pediatric primary hypertension, serum uric acid is high; what does allopurinol do in this case? Why did some primates lose the uricase mutation? What can we learn from the primate zoo? From examination of blood pressure in primitive cultures? How might uric acid interface with the low nephron number hypothesis? How might serum uric acid intrapartum affect nephron number? What does induced hyperuricemia do to the kidneys and blood pressure of rats? Which mediators are involved?
ASN Renal Week
audiofiles
Now in MP3Audiofile selection - ASN 2003 (San Diego) (5-10 talks)
Pancreas and Islet Cell Transplantation
- Simultaneous Pancreas, Kidney Transplantation (SPK), Pancreas After Kidney Transplantation (PAK), or Pancreas Transplantation Alone (PTA);
- Long-Term Benefits of Pancreas Transplantation;
- Update on Islet Cell Transplantation
(Klassen, Becker, Hayek) (more...)
Puzzling Cases of CKD: Common Syndromes, Uncommon Disorders
- Patients with Hematuria, Proteinuria, and Progressive Renal Failure; Case 1, a young woman; Case 2, a young man;
- Patients with Nephrotic Syndrome and Renal Failure; Case 1, A young man; Case 2, an older man.
(Adler, Grunfeld, Korbet, Glassock) (more...)
ADC
audiofiles
Now in MP3Audiofile selection - ADC 2004 (San Antonio) (5-10 talks)
Issues Related to Initiation and Termination of Dialysis
- The Patient Approaching ESRD - Depression and Choices;
- When and How to Terminate Dialysis
(Piraino, Lindsay) (more...)
Making Sense of Cardiovascular Risk Factors in Dialysis: Significance of `Reverse Epidemiology`
- Is Hypercholesterolemia Protective for Dialysis Patients? ;
- Other `Paradoxes' in Dialysis Patients with Possible Explanations for `Reverse Epidemiology' ;
- Is Obesity Protective for Dialysis Patients?
(Lowrie, Kalantar-Zadeh, Kopple) (more...)
Predictors of Low Hemoglobin Levels: Are Your Patients at Risk?
- Hospitalized Patients and Chronic Infection/ Inflammation ;
- What Are the Implications of Low Hemoglobin Levels?
(Benz, Pisoni) (more...)
April 6 - 12, 2004
Uric Acid, the Kidney, and the Pathogenesis of Hypertension. Part One of Two.
(Richard Johnson, MD; ASN Renal Week; San Diego, November, 2003)
What was the Goldblatt hypothesis regarding causation of essential hypertension? What is the role of renal arteriolar lesions in salt-sensitivity? Can angiotensin II induction of arteriolopathy and hypertension be blocked by mycophenolate? What did Frederick Mahomed observe about hypertension in 1879? What is the evidence linking serum acid levels to hypertension? How does loss of uricase separate man from other mammals? What is the evidence in animals that uric acid is linked to renal arteriolopathy and hypertension? How does uric acid enter VSMC and what pathways does it activate? Next week: The clinical evidence in people and some fascinating anthropological observations.
ASN Renal Week
audiofiles
Now in MP3Therapeutic Targets for Treatment of Glomerulopathies
- Where We Are and Where We Need to Go;
- Therapeutic Targets Presented by Podocytes;
- Targeting the Endothelium.
(Couser, Shankland, Ballermann) (more...)
How to Manage the Patient with Severe Hyperparathyroidism
- The Role of Newer Agents to Supress Parathyroid Hormone Release;
- The Role of Parathyroidectomy: Surgical Issues;
- The Role of Parathyroidectomy: Medical Perspective
(Sprague, Fukagawa, Cohen) (more...)
Dilemmas in the ICU: Illustrative Case Discussions
- Combined Pulmonary and Renal Impairment: Difficulties in Distinguishing Volume Contraction from Volume Overload;
- Renal Challenges;
- Pathophysiology and Management of Patients with Polyuria, Azotemia, and Mild Hypercreatininemia
(Hollenberg, Dember, Mehta) (more...)
Aldosterone Mediated Heart and Renal Disease: Pathogenesis and Therapeutic Approaches
- The Biology of Aldosterone;
- The Cardiac and Renal Effects of Aldosterone: Preclinical Data
(Geller, Hostetter) (more...)
March 26 - April 1, 2004
Preserving Residual Renal Function in Diabetics After Initiating Dialysis
(Joanne Bargman, MD; ASN Renal Week; San Diego, November, 2003)
Why should we care about residual renal function in ESRD? What can we do in our patients to help maintain RRF? What processes should be avoid that may be harmful to RRF? Is peritoneal dialysis really better than hemodialysis in terms of maintaining RRF? Is there a role for ACE inhibitors? Are there any special features in terms of RRF in diabetics?
ASN Renal Week
audiofiles
Now in MP3Belding Scribner Award Lecture
- Recent Advances in Systemic Amyloidosis
(Pepys) (more...)
Stemming the Rising Tide of CKD
- How Should We Manage the Epidemic of CKD: Review of Data from US and Other Countries;
- Treatment of CKD: Review Recent Evidence and the Canadian Experience;
- Maximizing Hypertension Therapy and its Delivery in CKD;
- How Do We Identify and Treat CKD? Lessons from the NIH
(Coresh, Levin, Lewis, Hostetter) (more...)
Role of Humoral Immune Activation in Acute and Chronic Rejection
- Evil Humors: Antibody-Mediated Immune Responses in Renal Transplantation;
- Diagnostic Role of C4d in Acute and Chronic Renal Allograft Rejection.
(Zand, Nasdady) (more...)
Novel Insights into Parathyroid Hormone
- Genetics and Cell Biology of Parathyroid Gland Growth;
- Anabolic Actions of PTH on Bone;
- Calcimimetics and Calciolytics - Role in Optimizing PTH Secretion
(Drueke, Hock, Nemeth) (more...)
March 19 - 25, 2004
Evaluation and Management of the Hepatitis C Virus Infected Pretransplant Candidate
(David Roth, MD; ASN Renal Week; San Diego, November, 2003)
How do we diagnose and stage HCV pretransplant? When do we treat with interferon? What are the considerations involved in use of a kidney from an HCV-positive donor? How do we manage HCV-positive ESRD patients on the waiting list? Can we use ribavirin in this population? Is there a role for pegylated interferon? How does MMF affect outcome in HCV-positive transplantation?
ASN Renal Week
audiofilesTopics in Critical Care Nephrology: Acute Renal Failure (part II)
Renal Protection: The Role of Dialysis; How the Damaged Kidney Talks to Other Organs; Consequences of ARF: Pulmonary Dysfunction; Oxidative Stress and Metabolic Consequences; Economic Consequences of ARF and Renal Support; Target Inflammation; Nutritional and Metabolic Interventions; Debate: Dose of Dialysis in ARF - More Is Better; Witholding and Withdrawing Support ; Emerging Techniques for Extracorporeal Support
(Lameire, Kielar, Rabb, Himmelfarb, Chertow, Okusa, Ikizler, Ronco vs. Paganini, Moss, Ronco) (more...)
March 13 - 18, 2004
Post-transplant Diabetes Mellitus
(Matthew Weir, MD; ASN Renal Week; San Diego, November, 2003)
How do we define post-transplant DM? What is the incidence? What are the consequences in terms of graft and patient survival? Which immunosuppressive agents increase risk, and which reduce the risk? How can this problem best be managed?
ASN Renal Week
audiofilesTopics in Critical Care Nephrology: Acute Renal Failure (part I)
Mechanisms of Injury and Repair; Functional Changes in ARF; Natural History of ARF in the Critically Ill Patient; How Can We Diagnose ARF Early?; Defining and Classifying ARF: What Criteria?; Experimental Models for Renal Protection; Primary Prevention Strategies: What Works?; Post-Injury Protection: Targeting Apoptosis; Preventing Iatrogenic ARF
(Portilla, Blantz, Lameire, Starr, Mehta, Lieberthal, Tumlin, Dagher, Bennett) (more...)
March 5 - 12, 2004
Hemolytic Uremic Syndrome: Who Should Receive Plasma Exchange?
(Bernard S. Kaplan, MB, BCh; ASN Renal Week; San Diego, November, 2003)
What is new about the pathogenesis of hemolytic uremic syndrome and thrombotic microangiopathy? Should we no longer speak about HUS/TTP? How are metalloproteinases involved? How is Shiga-toxin HUS characterized? What is the role for plasma exchange and fresh-frozen plasma infusion in these disorders? Are plasmapheresis or FFP indicated for other forms of HUS or TTP? Where is the evidence for a benefit the strongest? (Source audiotape has equipment-induced hum.)
ASN Renal Week
audiofilesHypertension and Cardiovascular Disease in People with Kidney Disease: New Guidelines and Approaches to Reduce Cardiovascular and Renal Risks
Dialysis Hypertension and Hypotension: Underlying Mechanisms; Insulin Resistance and Renal Disease: The Linkage; Vascular Compliance: Impact on Cardiovascular and Renal Disease Risk; Advances in Antihypertensive Drug Treatment: JNC VII; Antihypertensive Drug Interactions in the Practice of Nephrology; Workshop: Resistant Hypertension - An Interactive Case-Based Approach; Microalbuminuria: The Kidney's Message about the Systemic Vasculature; Cost Effectiveness of Treating Blood Pressure: A Perspective from the Kidney; Management of Hypertension in Diabetes Mellitus; Management of Hypertension in the Pregnant Patient; Management of Hypertension in Renal Transplant Patients; Management of Hypertension in the Pre-ESRD Patient with Chronic Renal Insufficiency; Reducing the Hypertensive Mortality in Dialysis Patients: Systolic or Pulse Pressure - What's More Important?; Management of Hypertension in Dialysis Patients
(Victor, Hseuh, Franklin, Bakris, Sica, Toto, Tuttle, Elliot, Linas, Umans, Weir, Levin, Tobe, Peixoto) (more...)
February 25 - March 4, 2004
Vitamin D and the Prevention of Morbidity and Mortality in Dialysis Patients
(ASN Renal Week; Official Evening Symposium; San Diego, November, 2003)
Dr. Moe: Where are the nuclear and membrane receptors for vitamin D? What do they do? What does 24,25-D do? How does vitamin D affect bone? Urine calcium? How do we diagnose and treat vitamin deficiency in various stages of CKD? Dr. Schwartz: What diseases may be reduced by sunlight exposure? How might vitamin D affect diabetes? Prostate cancer? What are effects of vitamin D on apoptosis? Dr. London: What cardiovascular tissues respond to vitamin D? How is blood pressure and LVH related to vitamin D? Does vitamin D therapy increase calcification risk? How might vitamin D, apolipoprotein A1, and HDL cholesterol be related? Dr. Thadhani: How do the effects of paricalcitol differ from those of calcitriol? In the FMC database, how was survival improved with paricalcitol vs. calcitriol? What might account for an apparent survival benefit of vitamin D therapy?
SLE Nephritis in Different Clinical Populations: Therapeutic and Prognostic Considerations
(Howard Austin III, MD; ASN Renal Week; San Diego, November, 2003)
What might account for the poor prognosis of lupus in African Americans? Does this extend to Hispanics and Asians? What are the maternal, renal, and fetal prognoses in pregnant patients with lupus nephritis? How is this affected by antiphospholipid antibodies? What are various treatment options for lupus nephritis in pregnancy?
ASN Renal Week
audiofilesTransplantation Update: Immunobiology, Immunosuppression, and Complications ( part II )
Recent trends in kidney transplant outcomes; Induction antibody therapy; Maintenance immunosuppression regimens; Use of expanded criteria donors; Surrogate markers for allograft rejection; Clinical issues in pancreas and islet cell transplantation; Ethnic disparities; Post-transplant hypertension; Post-transplant infections and lymphoproliferative disease; Post-transplant hyperlipidemia; Post- transplant bone disease.
(Meier-Kriesche, Vincenti, McCauley, Danovitch, Hricik, Pirsch, Young, Cosio, Fishman, Bia) (more...)
February 18 - 24, 2004
Viral Diseases and Renal Transplantation
(ASN Renal Week; Official Evening Symposium; San Diego, November, 2003)
Dr. Pereira: When should donors from HCV+ kidneys be used? Should HCV+ ESRD patients be transplanted? How does this affect opportunities for antiviral therapy? How should liver disease be monitored? Dr. Brennan: What is the scope of CMV disease in transplantation? What is the role for prophylaxis and for how long should it be given? Dr. Hirsch: How do we deal with the problem of BK virus in renal transplantation? What are predisposing factors? How do we diagnose, and how should we treat? Dr. Limaye: HHV-6 and West Nile Virus - why should we be worried about them in a transplant setting?
Therapy in Ischemic Nephropathy: A Data Based Approach
(Stephen Textor, MD; ASN Renal Week; San Diego, November, 2003)
What is the natural course of ischemic renal disease? What are the optimum medical treatments? When is interventional therapy indicated, and what are the treatment results?
ASN Renal Week
audiofilesTransplantation Update: Immunobiology, Immunosuppression, and Complications ( part I )
T cell differentiation and cell cycle control; Memory T cells and transplantation; Transplantation tolerance; Endothelial cell and smooth muscle cell responses to alloantibodies; Transplant kidney pathology; PPARs - new approach to immunosuppression; Ischemia reperfusion injury; Update on xenotransplantation; Post-transplant diabetes mellitus
(Wells, Lakkis, Womer, Reed, Kelly, Kupiec-Wiglinski, Platt, Markell) (more...)
February 8 - 17, 2004
Morbidity & Mortality Across the CKD Continuum: Can A Renewed Focus on Anemia Improve Outcomes?
(ASN Renal Week; Official Evening Symposium; San Diego, November, 2003)
Dr. Pisoni: What does DOPPS tell us about prevalence and treatment of anemia across the world? What is the use of EPO and IV iron across different countries? Is the mortality benefit of anemia correction similar in various parts of the world? Dr. Kausz: Apart from anemia, what other factors can we control to help patients with CKD, especially in terms of retarding progression? What are the protective benefits of aspirin, beta- blockers, and statins in the CKD population? What can we do to improve vascular access and vaccination rates? Dr. Yee: Anemia remains under-recognized. It induces abnormal left ventricular geometry. Anemia aggravates heart failure and increases mortality risk in a variety of cardiovascular conditions including congestive heart failure and post myocardial infarction. Treatment is salutary. Dr. Wish: Are the NKF K/DOQI guidelines to treat anemia in CKD/ESRD still appropriate? Are there compelling data to suggest that currently available IV iron agents are dangerous? Are there any clinical differences in outcomes among patients treated with currently available IV iron agents? Are there ways to improve the risk/benefit ratio of IV iron therapy?
Role of Hepatitis C in the Immunopathogenesis of Glomerulonephritis and Cryoglobulinemia
(Warren Kupin, MD; ASN Renal Week; San Diego, November, 2003)
What is the prevalence and natural history of hepatitis C? How does cryoglobulinemia develop and what are its distinguishing features? What immune derangements commonly lead to lymphoma in hepatitis C infected patients? What is the clinical presentation of hepatitis C - related cryoglobulinemic renal disease, and how does one diagnose it?
ASN Renal Week
audiofilesPeritoneal Dialysis: Theoretical Principles, Recent Advances, and Practical Aspects (Part 2)
Long-term membrane preservation; Workshop: Infections; Importance of residual renal function; How to minimize malnutrition and inflammation; Key issues regarding cardiovascular disease; Continuous flow PD
(Topley, Piraino, Golper, Ikizler, Burkart, Amerling) (more...)
January 31 - February 7, 2004
HIV and Transplantation
(Barbara Murphy, MD; ASN Renal Week; San Diego, November, 2003)
Should all HIV positive patients be excluded from transplantation? Has the use of HAART changed the picture? If so, what should inclusion and exclusion criteria be? What are the common drug-drug interactions between immunosuppressive drugs and protease inhibitors and NNRTs? Do immunosuppressive drugs accelerate the progression of HIV disease? Do they retard progression of HIV? What do preliminary results show with regard to graft and patient survival in HIV patients?
ASN Renal Week
audiofilesPeritoneal Dialysis: Theoretical Principles, Recent Advances, and Practical Aspects
Introduction; Principles - Convection and Diffusion; Peritoneal membrane structure and physiology; Principles of PD adequacy; Management of diabetes and other special populations in PD; Anemia management; Cases in metabolic bone disease
(Clark, Krediet, Burkart, Lameire, Fishbane, Moe) (more...)
January 23 - 29, 2004
Mycophenolate Mofetil: Emerging Role in Glomerular Disease
(ASN Renal Week 2003; Official Evening Symposium; San Diego, November, 2003)
Dr. Appel: African Americans with lupus have worse outcomes, and studies need to address this population. When do we need cyclophosphamide, and what have randomized trials of MMF shown in lupus? Dr. Contreras: When MMF is used as maintenance therapy vs. azathioprine or intermittent pulse cyclophosphamide, what are the results? Dr. Choi: What do we know about use of MMF in minimal change disease, focal sclerosis, and membranous nephropathy? What is the design on the randomized FSGS trial sponsored by NIH that is just getting underway? Dr. Hogg: What has experience been with MMF in treating IgA nephropathy? What is the design of the new randomized trial of MMF in IGAN?
Dialysis Dose in Acute Renal Failure: Measurement, Prescription, and Delivery
(Emil Paganini, MD; ASN Renal Week 2003; San Diego, November, 2003)
What is the consensus around ARF treatment as put together by the ADQI group? How should one treat an illustrative ICU case? What are implications of delayed onset ARF and what is the effect of timing of initiation of CRRT on outcomes? When should one choose intermittent vs. continuous therapy? What should the dose of dialysis be? Can we predict rebound? What is the variability in urea generation? What is the urea distribution volume in ARF? How can we use common equations, including rebound equations and formulas for EKR?
ASN Renal Week
audiofilesEssentials of Diagnostic and Interventional Nephrology ( Part II )
Thrombectomy case; Planning vascular access procedures - ultrasound vs. angiography; Use of techniques for grafts / fistulas; Monitoring graft / fistula function; Vein mapping for optimal fistula placement; Peritoneal catheter insertion and removal
(Rasmussen, Sands, Schon, Besarab, Vo, Ash) (more...)
January 16 - 22, 2004
Chronic Kidney Disease: Emerging Strategies for Managing the Cardio-Renal Syndrome
(ASN Renal Week 2003; Official Evening Symposium; San Diego, November, 2003)
Dr. McClellan: Patients with cardiovascular disease have a high prevalence of CKD that needs to be recognized and treated. Dr. Silverberg: Congestive heart failure can trigger anemia, and treatment of anemia in patients with congestive heart failure can result in marked clinical improvement. Dr. Singh: Epoetin alfa can be given subcutaneously every 2, 3, or even every 4 weeks with substantial benefit in terms of maintaining Hb within K-DOQI guidelines. Dr. Parfrey: Target Hb levels in CKD and ESRD are not yet known, but normalization is probably not required and may not be desirable. In addition to ACE inhibitors, beta-blocker therapy and use of anti-platelet agents can improve cardiovascular outcomes in CKD and ESRD patients. Statin use shows outcome benefits, and antioxidants may also have a role.
Nutritional Assessment and Management: When and What to Prescribe
(T. Alp Ikizler, MD; ASN Renal Week 2003; San Diego, November, 2003)
Nutritional support questions are addressed in the context of several presented cases: When should nutritional support be inititated? What route should be used? Which methods of enteral nutrition entail the greatest risk of aspiration? How many calories should the patient receive? How much protein?
ASN Renal Week
audiofilesEssentials of Diagnostic and Interventional Nephrology ( Part I )
Vascular anatomy; Salvage procedure for marginal or failed AV fistula; Stents - indications, contraindications, devices, techniques, complications, case presentations; Tunneled venous catheters; Fistula case; Angioplasty case.
(Levine, Beathard, Saad, Yu, Mishler) (more...)
January 7 - 14, 2004
Making Sense: A Scientific Approach to IV Iron
(ASN Renal Week 2003; Official Luncheon Symposium; San Diego, November, 2003)
Dr. Danielson: What are the chemical structures and iron core sizes of iron dextran, sucrose, and gluconate? What are their plasma half-lives? Where does labelled IV iron go after injection into the body? Dr. Aronoff: What did the USRDS study show regarding mortality and IV iron dextran use? What were results from the North American trials? The European EPIBACDIAL trial? Does IV iron increase the risk of infection? Of oxidative damage? Of cardiovascular risk? Should we give IV iron above a ferritin level of 500 ng/mL? Dr. Van Wyck: What is labile iron? Does it occur with dextran, gluconate and sucrose? What is the relation of IV iron core size to various measures of labile iron, including direct donation to transferrin? What are the signs and symptoms of a free iron reaction, and at what infusion rates are these seen with available preparations?
Literature Review: A Year in Nephrology - Fluids and Electrolytes
(Jose Arruda, MD; ASN Renal Week 2003; San Diego, November, 2003)
How are WNK1 and WNK4 involved in Gordon's syndrome? Does this involve the Na-Cl cotransporter directly? What is new about distal RTA and mutations in H-ATPase? Which subunit defects are associated with hearing loss? How is the anion exchanger involved in Southeast Asia ovalocytosis? How does Dent's disease affect chloride transport, PTH, and phosphaturia? New clinical papers: HIV and acidosis; Metabolic alkalosis after liver transplantation; Hyperkalemia with aldosterone antagonists; Hyponatremia in marathon runners; Use of vasopressin antagonists to treat hyponatremia; Renal salt wasting vs. SIADH.
ASN Renal Week
audiofilesUnlocking the Secrets to Treating Acute Renal Failure
Patient stratification in PICARD; ARF as a multidimensional disease process; Repopulation of the kidney with bone marrow stem cells after injury.
(Mehta, Star, Cantley) (more...)
Literature Review - The Year in Nephrology: Renal Parenchymal Diseases and Fluids & Electrolytes
Parenchymal disorders; Fluids and Electrolytes (see full slide/audio this week)
(Salant, Arruda) (more...)
Vascular Biology: Understanding the Role of Renal Vasculature in Disease Processes
Endothelial activation: Intracellular signaling; Uric acid makes a comeback
(Pober, Johnson) (more...)
December 31 - January 6, 2004
Potassium: Key Physiologic Principles, Hypokalemic and Hyperkalemic Disorders. Part 2 of 2.
(Biff Palmer, MD; ASN Board Review Course; San Francisco, August, 2003)
How do various diuretics and disturbances in renal sodium and potassium handling increase distal delivery and increase renal K excretion? How do calcium and magnesium handling differ in Bartter and Gitelman syndromes? What is the workup for hyperkalemia? How do different forms of acidosis cause or not cause hyperkalemia? What is the mechanism of hyperkalemic periodic paralysis? How do the pathogeneses of pseudohypoaldosteronism types I and II differ? What is current management of acute and chronic hyperkalemia?
ASN Renal Week
audiofilesBone in ESRD: Abnormal Bone Turnover or Bone Mass or Both?
Biomechanics of fracture; Osteoprotegerin / RANK ligand; Bisphosphonates and statins - the mevalonate pathway in bone; The cardiovascular - bone link
(Turner, Dunstan, Mundy, Price) (more...)
New Insights into Immunosuppressive Therapy
Tolerance induction protocols; The high risk recipient; Immunosuppressive therapy for the high risk patient; Immunosuppression in pediatric patients: Ideal candidates for minimization
(Vincenti, Gaston, Knechtle, Harmon) (more...)
HDCN home /about our site / subscribe to key zone / register for free zone
update email
address / subscription status / forget your
password?
